Shawn K. Singh
Chief Executive Officer and Director
Shawn K. Singh has served as our Chief Executive Officer since August 2009; he joined our Board of Directors in 2000 and served on our management team (part-time) from late-2003, following our acquisition of Artemis Neuroscience, of which he was President, to August 2009. Mr. Singh has over 25 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO), serving in numerous senior management roles. Prior to joining VistaGen as Chief Executive Officer, Mr. Singh served as Managing Principal of Cato BioVentures, a healthcare-focused venture capital firm, and as Chief Business Officer and General Counsel of Cato Research Ltd, a profitable global CRO affiliated with Cato BioVentures. Earlier, Mr. Singh served as Chief Business Officer of SciClone Pharmaceuticals (Nasdaq: SCLN), a US-based, China-focused specialty pharmaceutical company with a substantial revenue-generating and profitable commercial business and a marketed product portfolio of differentiated therapies for oncology, infectious diseases and cardiovascular disorders. He began his career as a corporate finance attorney in the Silicon Valley offices of Morrison & Foerster LLP, an international law firm. Mr. Singh earned a B.A. degree, with honors, from the University of California, Berkeley, and a J.D. degree from the University of Maryland School of Law. He is a member of the State Bar of California.
H. Ralph Snodgrass, Ph.D.
Founder, President, Chief Scientific Officer and Director
Dr. Snodgrass co-founded VistaGen with Dr. Gordon Keller in 1998 and served as our Chief Executive Officer until August 2009. He has more than 20 years of experience in senior biotechnology management and is recognized as an expert in stem cell biology with more than 28 years' experience in the uses of stem cells as biological tools for research, drug discovery and development. Prior to founding VistaGen, Dr. Snodgrass served as a key member of the executive management team that led Progenitor, Inc., a biotechnology company focused on developmental biology, through its initial public offering, and was its Chief Scientific Officer and Executive Director. Dr. Snodgrass also has over 10 years of research experience as a professor at the Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill School of Medicine, and served as a member of the Institute for Immunology, Basel, Switzerland. He is a former Board Member of the Emerging Company Section of the Biotechnology Industry Organization (BIO), and a former member of the International Society Stem Cell Research Industry Committee. Dr. Snodgrass has published more than 50 scientific papers, is the inventor of more than 17 patents and a number of patent applications, and is or has been, the Principal Investigator on U.S. federal and private foundation sponsored research grants with budgets totaling more than $14.5 million. He received his Ph.D. in immunology from the University of Pennsylvania.
Mark A. Smith, M.D., Ph.D.
Chief Medical Officer
Mark A. Smith, M.D, Ph.D. joined VistaGen as our Chief Medical Officer in June 2016. Dr. Smith has more than 20 years of pharmaceutical industry experience in CNS drug development. He has been a successful project leader in both discovery and development resulting in approximately 20 investigational new drugs (INDs). Dr. Smith has directed clinical trials aimed at depression, bipolar disorder, anxiety, schizophrenia, Alzheimer's, ADHD and agitation in Phase 1 through Phase 2b and has vast knowledge and expertise in drug discovery and development, translational neuroscience, clinical trial design and regulatory interactions. Prior to joining VistaGen, Dr. Smith served as the Clinical Lead for Neuropsychiatry at Teva Pharmaceuticals (NYSE: TEVA), where he was accountable for the strategy and clinical development of neuropsychiatric drugs through all phases of development with a focus on schizophrenia, sleep disorders and agitation. Previously, Dr. Smith held a range of director positions including Executive Director of Clinical Development at AstraZeneca Pharmaceutical Company (NYSE: AZN) where he led the early development of several novel chemical entities targeting treatment-resistant depression, anxiety and schizophrenia. Dr. Smith has also held positions as Senior Director of Experimental Medicine of Global Clinical Development and Innovation at Shire Pharmaceuticals (Nasdaq: SHPG) and served as Senior Investigator and Principal Research Scientist of CNS Diseases at DuPont Pharmaceuticals (NYSE: DD). Prior to joining the pharmaceutical industry, he served as a Senior Staff Scientist of the Biological Psychiatry Branch and Senior Staff Fellow of the Clinical Neuroendocrinology Branch at the U.S. National Institute of Mental Health (NIMH). Dr. Smith received his Bachelor's degree and Master of Science from Yale University, his Doctor of Medicine and Doctor of Philosophy in Physiology and Pharmacology from the University of California, San Diego and completed his residency in the Department of Psychiatry at Duke University Medical Center.
Jerrold D. Dotson, CPA
Vice President, Chief Financial Officer and Secretary
Jerrold D. Dotson, CPA has served as our Chief Financial Officer since September 2011, as our Corporate Secretary since October 2013 and as a Vice President since February 2014. Mr. Dotson previously served as Corporate Controller for Discovery Foods. Mr. Dotson also held various positions in the finance and administration department of Calypte Biomedical Corporation, including his last position as Vice President of Finance and Administration. Prior to joining Calypte, Mr. Dotson worked in various financial management positions, including Chief Financial Officer, for California & Hawaiian Sugar Company, a privately held company. Mr. Dotson is licensed as a CPA in California and received his B.S. degree (Cum Laude) in Business Administration with a concentration in accounting from Abilene Christian College.
Mark A. McPartland
Vice President of Corporate Development
Prior to joining VistaGen, Mr. McPartland served as the Vice President of Corporate Development and Communications at Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leader in sustainable manufacture of KLH, an immune-stimulating protein widely used in the field of active immunotherapy. While at Stellar, Mr. McPartland was responsible for transforming and expanding its capital markets and corporate communications strategy, while also supporting its global business development activities. Prior to Stellar, Mr. McPartland served as Senior Vice President at MZ Group, a subsidiary of @titude Global, the world's largest independent global IR consulting firm. His prior experience includes Vice President and Partner at Alliance Advisors, LLC where he specialized in the implementation of capital markets strategy, market positioning and financial communications, and Regional Vice President of Hayden Communications, Inc. where he led investor relations and corporate communications programs for micro and small cap companies.
Mr. McPartland received his Bachelors in Business Administration and Marketing from Coastal Carolina University.